Metrics to compare | HEMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHEMOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −8.6x | −0.5x | |
PEG Ratio | 0.18 | −0.17 | 0.00 | |
Price/Book | −86.9x | 1.6x | 2.6x | |
Price / LTM Sales | - | 10.4x | 3.2x | |
Upside (Analyst Target) | - | 197.4% | 47.8% | |
Fair Value Upside | Unlock | −4.6% | 6.7% | Unlock |
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.